MétaCan
Menu
Back to cohort
Record W3080899364 · doi:10.1080/24745332.2018.1512840

Cost-effectiveness of universally funding smoking cessation pharmacotherapy

2018· article· en· W3080899364 on OpenAlexaffabout
Daniel Altman, Fiona Clement, Lianne Barnieh, Braden Manns, Erika Penz

Bibliographic record

VenueCanadian Journal of Respiratory Critical Care and Sleep Medicine · 2018
Typearticle
Languageen
FieldMedicine
TopicSmoking Behavior and Cessation
Canadian institutionsLibin Cardiovascular Institute of AlbertaUniversity of CalgaryUniversity of Saskatchewan
FundersGlaxoSmithKline
KeywordsSmoking cessationPharmacotherapyMedicineBusinessInternal medicine

Abstract

fetched live from OpenAlex

RATIONALE: Tobacco use is the leading cause of preventable death in Canada and worldwide. Funding smoking cessation pharmacotherapy increases the likelihood of smoking cessation pharmacotherapy use, making a quit attempt, and the probability of abstinence from smoking.OBJECTIVES: The aim of our study was to model the cost-effectiveness of a health policy of funding smoking cessation pharmacotherapy for all Canadian smokers at no cost to the patient.METHODS: Using data from a Cochrane Review meta-analysis, a decision model incorporating utilization of smoking cessation products, quit rates, six-month continuous abstinence rates, relapse rate, and direct costs of smoking cessation pharmacotherapy and physician visits associated with full funding of smoking cessation pharmacotherapy for one quit attempt compared to no funding was constructed, and a sensitivity analysis was conducted incorporating variation in all inputs used. Our primary outcome was the incremental cost per life-year gained from universally funding smoking cessation pharmacotherapy compared to no funding for the average Canadian smoker.RESULTS: The average incremental cost per life-year gained of funding smoking cessation pharmacotherapy compared to no funding in the overall population was CaD$1030 (range CaD$250–10,040) per life-year gained. In our cost-effectiveness analysis, the probability that universally funding smoking cessation pharmacotherapy is cost-effective is >95% at a willingness-to-pay threshold as low as CaD$10,000 per life year gained.CONCLUSION: Universally funding smoking cessation pharmacotherapy appears cost-effective when compared to currently funded interventions in our healthcare system. Policy makers and government decision makers should fully fund smoking cessation pharmacotherapy for all Canadian smokers.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.122
Threshold uncertainty score0.366

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.095
GPT teacher head0.389
Teacher spread0.293 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2018
Admission routes2
Has abstractyes

Explore more

Same venueCanadian Journal of Respiratory Critical Care and Sleep MedicineSame topicSmoking Behavior and CessationFrench-language works237,207